Company intelligence
Evotec
Pioneering Drug Discovery
About Evotec
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
Verified activity
Signals from Evotec
16 published signals
Presence & Recognition
Evotec is presenting efforts toward embedding greener chemistry practices in its drug discovery pipeline at the 7th International Conference on Free Chemistry in Lisbon.
Reported by Evotec
Presence & Recognition
Evotec is participating in the Virtual Cell Challenge 2026
Reported by Evotec
Presence & Recognition
Evotec participated in the shaping of predictive biology.
Reported by Francisco Cruzalegui
Products & Services
Evotec provides cutting-edge testing strategies and best practices for genetic integrity testing of genome-edited pluripotent stem cell lines to support clinical applications.
Reported by Carla Tameling
Research & Knowledge
Evotec published the Mind and Machine Weekly 5 September edition featuring AI-related news.
Reported by Rui Wang
Presence & Recognition
Evotec contributed to the ERS Congress in Barcelona with two scientific poster presentations showcasing research advancements in the respiratory disease field.
Reported by Evotec
Presence & Recognition
Evotec is participating in the CTSS London event on 30th September.
Reported by Helen Box
Presence & Recognition
Evotec is attending the MCT community in Munich.
Reported by Mikhail Alekov
Presence & Recognition
Evotec experts discuss a holistic approach to de-risking and development built on horizontal and vertical integration on 7th of September.
Reported by Evotec
Research & Knowledge
Evotec contributed to the publication of a review in Signal Transduction and Targeted Therapy on macrophage signaling and scalable engineering for immunotherapy cells.
Reported by Evotec
Partnerships
Evotec SE and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors using Evotec's BiTco platform and Plectonic's programmable LOGIBODY technology.
Reported by Evotec
People
Evotec is hiring an Associate Scientist for the Toxicology team at Cyprotex in Alderley Park on a 6-month FTC.
Reported by Marie Ariyaratne
Research & Knowledge
Evotec published a case study on Cyprotex's tailored LC-MS/MS bioanalytical methods for peptide therapeutics.
Reported by Marc Hendrick
Presence & Recognition
Evotec contributed to the 14th GSCN Conference 2026 in Berlin with three oral presentations showcasing human iPSC-based platforms advancing drug discovery and next-generation cell therapies.
Reported by Evotec
Strategy & Corporate Development
Evotec's CEO highlighted the Environmental Commitment Statement, which emphasizes embedding environmental responsibility into the company's business to support scientific innovation and reduce environmental footprint.
Reported by Carla Tameling
Research & Knowledge
Evotec addresses key challenges and testing strategies to maintain clinical standards for ensuring the genetic integrity of genome-edited pluripotent stem cell lines.
Reported by Marc Hendrick